140 related articles for article (PubMed ID: 12741824)
21. Affinity transfer by CDR grafting on a nonimmunoglobulin scaffold.
Nicaise M; Valerio-Lepiniec M; Minard P; Desmadril M
Protein Sci; 2004 Jul; 13(7):1882-91. PubMed ID: 15169956
[TBL] [Abstract][Full Text] [Related]
22. Role of steric effects in protein-directed enediyne cycloaromatization of neocarzinostatin.
Chi HW; Chien YC; Liu CY; Tseng CJ; Lee YJ; Chan JL; Chu YR; Chin DH
Chemistry; 2011 Feb; 17(5):1493-506. PubMed ID: 21268152
[TBL] [Abstract][Full Text] [Related]
23. Molecular dynamics simulations investigation of neocarzinostatin chromophore-releasing pathways from the holo-NCS protein.
Zhao X; Wang S; Gao XF; Huang XR; Sun CC
J Struct Biol; 2010 Jan; 169(1):14-24. PubMed ID: 19747549
[TBL] [Abstract][Full Text] [Related]
24. Protein-small molecule interactions in neocarzinostatin, the prototypical enediyne chromoprotein antibiotic.
Baker JR; Woolfson DN; Muskett FW; Stoneman RG; Urbaniak MD; Caddick S
Chembiochem; 2007 May; 8(7):704-17. PubMed ID: 17451164
[TBL] [Abstract][Full Text] [Related]
25. Selection and characterization of Affibody ligands to the transcription factor c-Jun.
Lundberg E; Brismar H; Gräslund T
Biotechnol Appl Biochem; 2009 Jan; 52(Pt 1):17-27. PubMed ID: 18260830
[TBL] [Abstract][Full Text] [Related]
26. Increased folding stability of TEM-1 beta-lactamase by in vitro selection.
Kather I; Jakob RP; Dobbek H; Schmid FX
J Mol Biol; 2008 Oct; 383(1):238-51. PubMed ID: 18706424
[TBL] [Abstract][Full Text] [Related]
27. Monitored whole gene in vitro evolution of an anti-hRaf-1 affibody molecule towards increased binding affinity.
Grimm S; Salahshour S; Nygren PÅ
N Biotechnol; 2012 Jun; 29(5):534-42. PubMed ID: 22027369
[TBL] [Abstract][Full Text] [Related]
28. The proteolytic specificity of the natural enediyne-containing chromoproteins is unique to each chromoprotein.
Zein N; Reiss P; Bernatowicz M; Bolgar M
Chem Biol; 1995 Jul; 2(7):451-5. PubMed ID: 9383447
[TBL] [Abstract][Full Text] [Related]
29. Insight into the strong inhibitory action of salt on activity of neocarzinostatin.
Chin DH; Li HH; Sudhahar CG; Tsai PY
Bioorg Med Chem; 2010 Mar; 18(5):1980-7. PubMed ID: 20137955
[TBL] [Abstract][Full Text] [Related]
30. Phage display and crystallographic analysis reveals potential substrate/binding site interactions in the protein secretion chaperone CsaA from Agrobacterium tumefaciens.
Feldman AR; Shapova YA; Wu SS; Oliver DC; Heller M; McIntosh LP; Scott JK; Paetzel M
J Mol Biol; 2008 Jun; 379(3):457-70. PubMed ID: 18462752
[TBL] [Abstract][Full Text] [Related]
31. Mouse 17alpha-hydroxysteroid dehydrogenase (AKR1C21) binds steroids differently from other aldo-keto reductases: identification and characterization of amino acid residues critical for substrate binding.
Faucher F; Cantin L; Pereira de Jésus-Tran K; Lemieux M; Luu-The V; Labrie F; Breton R
J Mol Biol; 2007 Jun; 369(2):525-40. PubMed ID: 17442338
[TBL] [Abstract][Full Text] [Related]
32. Transposon Tn7 protein TnsD binding to Escherichia coli attTn7 DNA and its eukaryotic orthologs.
Chakrabarti A; Desai P; Wickstrom E
Biochemistry; 2004 Mar; 43(10):2941-6. PubMed ID: 15005630
[TBL] [Abstract][Full Text] [Related]
33. Neocarzinostatin chromophore. Assignment of spectral properties and structural requirements for binding to DNA.
Napier MA; Goldberg IH
Mol Pharmacol; 1983 Mar; 23(2):500-10. PubMed ID: 6220205
[TBL] [Abstract][Full Text] [Related]
34. Ligand specificity in the CRAL-TRIO protein family.
Panagabko C; Morley S; Hernandez M; Cassolato P; Gordon H; Parsons R; Manor D; Atkinson J
Biochemistry; 2003 Jun; 42(21):6467-74. PubMed ID: 12767229
[TBL] [Abstract][Full Text] [Related]
35. Selection and characterization of anti-MUC-1 scFvs intended for targeted therapy.
Winthrop MD; DeNardo SJ; Albrecht H; Mirick GR; Kroger LA; Lamborn KR; Venclovas C; Colvin ME; Burke PA; DeNardo GL
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3845S-53S. PubMed ID: 14506182
[TBL] [Abstract][Full Text] [Related]
36. Solution structure of a novel chromoprotein derived from apo-neocarzinostatin and a synthetic chromophore.
Urbaniak MD; Muskett FW; Finucane MD; Caddick S; Woolfson DN
Biochemistry; 2002 Oct; 41(39):11731-9. PubMed ID: 12269815
[TBL] [Abstract][Full Text] [Related]
37. Selection and characterization of an HIV-1 gp120-binding affibody ligand.
Wikman M; Rowcliffe E; Friedman M; Henning P; Lindholm L; Olofsson S; Ståhl S
Biotechnol Appl Biochem; 2006 Sep; 45(Pt 2):93-105. PubMed ID: 16712522
[TBL] [Abstract][Full Text] [Related]
38. Key interactions in the immunoglobulin-like structure of apo-neocarzinostatin: evidence from nuclear magnetic resonance relaxation data and molecular dynamics simulations.
Izadi-Pruneyre N; Quiniou E ; Blouquit Y; Perez J; Minard P; Desmadril M; Mispelter J; Adjadj E
Protein Sci; 2001 Nov; 10(11):2228-40. PubMed ID: 11604530
[TBL] [Abstract][Full Text] [Related]
39. Directed evolution for the development of conformation-specific affinity reagents using yeast display.
Weaver-Feldhaus JM; Miller KD; Feldhaus MJ; Siegel RW
Protein Eng Des Sel; 2005 Nov; 18(11):527-36. PubMed ID: 16186140
[TBL] [Abstract][Full Text] [Related]
40. Neocarzinostatin as a probe for DNA protection activity--molecular interaction with caffeine.
Chin DH; Li HH; Kuo HM; Chao PD; Liu CW
Mol Carcinog; 2012 Apr; 51(4):327-38. PubMed ID: 21538576
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
